All
  • All
  • Insight
  • Research Services
  • Preclinical CRO
  • Animal Resource Bank

Animal model of thermal and scald burns


Animal model of thermal and scald burns

Explore more

Burns and scalds
Psychiatric & neurological disease models

Burns and scalds

Introduction to TI Animal Models

The thermal injury (TI) mouse model induces controlled thermal damage to the skin through exposure to high‑temperature liquids, contact with hot metals, or constant‑temperature heating, serving as a classic animal model for simulating the local tissue injury and systemic inflammatory responses observed in human burns and scalds. This model reliably reproduces key pathological processes, including skin erythema and edema, blister formation, tissue necrosis, inflammatory cell infiltration, oxidative stress, and wound healing, accompanied by cytokine release, angiogenesis, and collagen remodeling. Depending on the severity of the injury, it can be used to establish superficial second‑degree, deep second‑degree, and third‑degree burn models, characterized by ease of operation, excellent reproducibility, and precise control over the extent of tissue damage.

Advantages of Aniphe BioLab’s TI Animal Model Platform Services

Relying on its established expertise in trauma model development and a standardized pharmacological efficacy evaluation system, Aniphe BioLab offers stable, highly reproducible animal models of thermal burns (TI), providing a robust in vivo research platform for wound healing and the development of innovative therapeutics.

 Comprehensive model coverage

Mature modeling system

It supports the establishment of models with varying burn depths and lesion areas, ensuring stable and highly consistent model generation.

 Standardization of the modeling process

Multidimensional Efficacy Evaluation

It encompasses evaluation metrics such as wound‑healing rate, histopathology, inflammatory cytokines, collagen deposition, angiogenesis, and immunohistochemistry, providing a comprehensive assessment of therapeutic efficacy.

 Multidimensional Evaluation System

Standardized Quality Management

A comprehensive SOP and QA quality-control system ensures standardized, consistent procedures for model generation, drug administration, sample collection, and data analysis, thereby guaranteeing the authenticity, reliability, and traceability of experimental data.

 Adaptable to multi-cycle studies

Customized Research Services

It supports personalized efficacy evaluation for a variety of therapeutic approaches, including topical formulations, bio‑dressings, stem cells, biomaterials, and innovative drugs, thereby meeting diverse R&D needs.

Modeling cycle

2–8 weeks

1  Laboratory animals

BALB/c mice

1  Positive drug

Commonly used topical agents include silver sulfadiazine cream, recombinant human epidermal growth factor (rhEGF), recombinant bovine basic fibroblast growth factor (rbFGF), and mupirocin ointment, among others.

1  Application areas

It is widely used in research on the mechanisms of burn wound healing, evaluation of anti-inflammatory and anti-infective drugs, screening of growth factors and bioactive molecules that promote tissue repair, development of biological dressings and wound‑care materials, stem cell and tissue engineering studies, as well as preclinical efficacy and safety assessments of innovative therapeutics and medical devices for burn repair.

Construction of TI animal models

A simulated burn‑surgery modeling method is employed: after anesthetizing the animals, the dorsal fur is shaved, and a preheated metal block or heating device maintained at a set temperature is applied to the skin under a fixed pressure for a specified duration, thereby inducing controlled thermal injury and establishing burn models of varying severity. This approach reliably elicits localized skin erythema, blisters, tissue necrosis, and inflammatory responses, with features such as controllable injury depth, excellent reproducibility, and model stability, making it widely used in preclinical studies of burn wound healing and related therapeutics.